PharaMar names Besman new chief operating officer

PharmaMar has named Pascal Besman as its new chief operating officer, effective immediately.
"With Yondelis on the market in the US and our key pipeline program PM1183 in several pivotal Phase 3 studies, now is the ideal time to welcome Pascal to our team as we further expand our presence in the U.S.," PharmaMar President, CEO and Chairman of the Board José María Fernández Sousa-Faro said. "As a global, revenue-generating oncology company, we look forward to leveraging Pascal's expertise in the biotechnology sector and U.S. capital markets as we continue to expand our efforts in the US."
Besman's responsibilities will include overseeing the implementation of PharMar’s operational infrastructure in the U.S.
"I have been impressed with PharmaMar's progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines," Besman said. "PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company's future success as we seek to continue building shareholder value."